|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar
|
|
3
|
Miyamoto Y, Hosotani R, Wada M, et al:
Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1
expression in pancreatic cancers. Oncology. 56:73–82. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei Y, Kadia T, Tong W, et al: The
combination of a histone deacetylase inhibitor with the Bcl-2
homology domain-3 mimetic GX15-070 has synergistic antileukemia
activity by activating both apoptosis and autophagy. Clin Cancer
Res. 16:3923–3932. 2010. View Article : Google Scholar
|
|
5
|
McCoy F, Hurwitz J, McTavish N, et al:
Obatoclax induces Atg7-dependent autophagy independent of beclin-1
and BAX/BAK. Cell Death Dis. 1:e1082010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Konopleva M, Watt J, Contractor R, et al:
Mechanisms of anti-leukemic activity of the novel Bcl-2 homology
domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68:3413–3420.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen M, Marcellus RC, Roulston A, et al:
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes
MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA.
104:19512–19517. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rahmani M, Aust MM, Attkisson E, Williams
DC Jr, Ferreira-Gonzalez A and Grant S: Inhibition of Bcl-2
antiapoptotic members by obatoclax potently enhances
sorafenib-induced apoptosis in human myeloid leukemia cells through
a Bim-dependent process. Blood. 119:6089–6098. 2012. View Article : Google Scholar
|
|
9
|
Chen S, Wang G, Niu X, et al: Combination
of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in
synergistic antitumor activities in preclinical models of
pancreatic cancer. Cancer Lett. 348:20–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maiuri MC, Zalckvar E, Kimchi A and
Kroemer G: Self-eating and self-killing: crosstalk between
autophagy and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang Z and Klionsky DJ: Mammalian
autophagy: core molecular machinery and signaling regulation. Curr
Opin Cell Biol. 22:124–131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malik SA, Orhon I, Morselli E, et al: BH3
mimetics activate multiple pro-autophagic pathways. Oncogene.
30:3918–3929. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan J, Cheng C, Verstovsek S, Chen Q, Jin
Y and Cao Q: The BH3-mimetic GX15-070 induces autophagy,
potentiates the cytotoxicity of carboplatin and 5-fluorouracil in
esophageal carcinoma cells. Cancer Lett. 293:167–174. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vogler M, Weber K, Dinsdale D, et al:
Different forms of cell death induced by putative BCL2 inhibitors.
Cell Death Differ. 16:1030–1039. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maiuri MC, Criollo A, Tasdemir E, et al:
BH3-only proteins and BH3 mimetics induce autophagy by
competitively disrupting the interaction between Beclin 1 and
Bcl-2/Bcl-X(L). Autophagy. 3:374–376. 2007. View Article : Google Scholar
|
|
16
|
Hashimoto D, Blauer M, Hirota M, Ikonen
NH, Sand J and Laukkarinen J: Autophagy is needed for the growth of
pancreatic adenocarcinoma and has a cytoprotective effect against
anti-cancer drugs. Eur J Cancer. 50:1382–1390. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang S, Wang X, Contino G, et al:
Pancreatic cancers require autophagy for tumor growth. Genes Dev.
25:717–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edwards H, Xie C, LaFiura KM, et al: RUNX1
regulates phosphoinositide 3-kinase/AKT pathway: role in
chemotherapy sensitivity in acute megakaryocytic leukemia. Blood.
114:2744–2752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie C, Edwards H, Xu X, et al: Mechanisms
of synergistic anti-leukemic interactions between valproic acid and
cytarabine in pediatric acute myeloid leukemia. Clinical cancer
research: an official journal of the American Association for
Cancer Research. 16:5499–5510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu X, Xie C, Edwards H, Zhou H, Buck SA
and Ge Y: Inhibition of histone deacetylases 1 and 6 enhances
cytarabine-induced apoptosis in pediatric acute myeloid leukemia
cells. PloS One. 6:e171382011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang G, He J, Zhao J, et al: Class I and
class II histone deacetylases are potential therapeutic targets for
treating pancreatic cancer. PloS One. 7:e520952012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maiuri MC, Le Toumelin G, Criollo A, et
al: Functional and physical interaction between Bcl-X(L) and a
BH3-like domain in Beclin-1. EMBO J. 26:2527–2539. 2007. View Article : Google Scholar : PubMed/NCBI
|
